Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW)University of Massachusetts Medical School, Worcester, MA, USA.
Leuven University Centre for Metabolic Bone Diseases, Division of Geriatric Medicine, Katholieke Universiteit Leuven, Leuven, Belgium.
Université de Lyon, Department of Orthopedics and Rheumatology, Hôpital E Herriot, Lyon, France.
University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, UK.
University of Southampton, Southampton General Hospital and Norman Collisson Chair of Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Hôpital Edouard Herriot, Lyon, France.
University of Pittsburgh, PA, USA.
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Regional Bone Center, Helen Hayes Hospital, West Haverstraw, NY, USA.
Department of Endocrinology, VU University Medical Center, Amsterdam, Netherlands.
Alfried Krupp Krankenhaus, Department of Internal Medicine III, Essen, Germany.
Paris Descartes University, Cochin Hospital, Paris, France.
University of Alabama-Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, USA.
University of Sydney-Royal North Shore Hospital, St. Leonards, Sydney, NSW, Australia.
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Columbia University Medical Center, New York, NY, USA.
Bone Health and Osteoporosis Center, University of Cincinnati, Cincinnati, OH, USA.
University of Massachusetts Medical School, Worcester, MA, USA.
Show others and affiliations
2011 (English)In: Bone, ISSN 8756-3282, E-ISSN 1873-2763, Vol. 49, no 3, p. 493-498Article in journal (Refereed) Published
Abstract [en]
PurposeTo determine if important geographic differences exist in treatment rates for osteoporosis and whether this variation can be explained by regional variation in risk factors.MethodsThe Global Longitudinal Study of Osteoporosis in Women is an observational study of women ≥ 55 years sampled from primary care practices in 10 countries. Self-administered questionnaires were used to collect data on patient characteristics, risk factors for fracture, previous fractures, anti-osteoporosis medication, and health status.ResultsAmong 58,009 women, current anti-osteoporosis medication use was lowest in Northern Europe (16%) and highest in USA and Australia (32%). Between 48% (USA, Southern Europe) and 68% (Northern Europe) of women aged ≥ 65 years with a history of spine or hip fracture since age 45 were untreated. Among women with osteoporosis, the percentage of treated cases was lowest in Europe (45–52% versus 62–65% elsewhere). Women with osteopenia and no other risk factors were treated with anti-osteoporosis medication most frequently in USA (31%) and Canada (31%), and least frequently in Southern Europe (12%), Northern Europe (13%), and Australia (16%). After adjusting for risk factors, US women were threefold as likely to be treated with anti-osteoporosis medication as Northern European women (odds ratio 2.8; 95% confidence interval 2.5–3.1) and 1.5 times as likely to be treated as Southern European women (1.5, 1.4–1.6). Up to half of women reporting previous hip or spine fracture did not receive treatment.ConclusionsThe likelihood of being treated for osteoporosis differed between regions, and cannot be explained by variation in risk factors. Many women at risk of fracture do not receive prophylaxis.
Place, publisher, year, edition, pages
Elsevier, 2011. Vol. 49, no 3, p. 493-498
National Category
Medical and Health Sciences Probability Theory and Statistics
Identifiers
URN: urn:nbn:se:kau:diva-88400DOI: 10.1016/j.bone.2011.05.007ISI: 000293805100022Scopus ID: 2-s2.0-79960618233OAI: oai:DiVA.org:kau-88400DiVA, id: diva2:1635172
2022-02-042022-02-042022-11-07Bibliographically approved